Author:
Hyman David M.,Solit David B.,Arcila Maria E.,Cheng Donavan T.,Sabbatini Paul,Baselga Jose,Berger Michael F.,Ladanyi Marc
Subject
Drug Discovery,Pharmacology
Reference20 articles.
1. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2;Slamon;N. Engl. J. Med.,2001
2. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer;Swain;N. Engl. J. Med.,2015
3. Improved survival with vemurafenib in melanoma with BRAF V600E mutation;Chapman;N. Engl. J. Med.,2011
4. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study;Zhou;Lancet Oncol.,2011
5. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer;Shaw;N. Engl. J. Med.,2013
Cited by
135 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献